Pathophysiology of pyoderma gangrenosum (PG): an updated review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26253362.
- Also identified by DOI 10.1016/j.jaad.2015.06.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pyoderma gangrenosum is a challenging skin condition to identify and treat because of its multifactorial pathogenesis. It is a rare cutaneous manifestation diagnosed clinically by exclusion of infection, neoplasia, thrombophilia, and other inflammatory conditions. Pathogenetic and treatment studies are scarce. Abnormalities in the function of inflammatory cytokines, the immune system, and neutrophils combined with specific genetic mutations predispose patients to develop this complex disease process. Early recognition of patients at risk for pyoderma gangrenosum, the necessity to improve its early diagnosis, and the future outlook of targeted and personalized therapies relies on the improved comprehension of the complex pathogenesis of pyoderma gangrenosum.
Medical subject headings
- Cytokines
- Genetic Testing
- Immunosuppressive Agents
- Pyoderma Gangrenosum